In sum, GLP-1 agonists associate with a reduced risk in CRC and a modest relative increase in thyroid cancer risk; however, further study is warranted to conclude whether and to what extent GLP-1 agonists elevate thyroid cancer risk. This evidence concerns the gene GCG and colorectal carcinoma.